We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effectiveness of Auto-adjusted Continuous Positive Airway Pressure for Long-term Treatment of Sleep Apnea

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00280800
First Posted: January 23, 2006
Last Update Posted: May 15, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
University of Zurich
Kantonsspital Münsterlingen
Zuercher Hoehenklinik Wald
Cantonal Hospital of St. Gallen
Information provided by (Responsible Party):
Konrad E. Bloch, University of Zurich
  Purpose
Hypothesis: Computer controlled continuous positive airway pressure (autoCPAP) is equally effective in improving obstructive sleep apnea syndrome symptoms, breathing disturbances, objective vigilance, and it is cost-effective compared to conventional fixed continuous positive airway pressure.

Condition Intervention
Sleep Apnea, Obstructive Device: constant CPAP devices Device: automatic CPAP devices

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effectiveness of Auto-adjusted Continuous Positive Airway Pressure for Long-term Treatment of Obstructive Sleep Apnea Syndrome

Resource links provided by NLM:


Further study details as provided by Konrad E. Bloch, University of Zurich:

Primary Outcome Measures:
  • subjective sleepiness and other OSAS symptoms [ Time Frame: 3 months, 1 year, 2 years ]
  • quality of life [ Time Frame: 3 months, 1 year, 2 years ]
  • percentage of withdrawal and cross-over to other CPAP mode [ Time Frame: 3 months, 1 year, 2 years ]
  • objective vigilance [ Time Frame: 3 months, 1 year, 2 years ]
  • blood pressure [ Time Frame: 3 months, 1 year, 2 years ]
  • cost/utility ratios [ Time Frame: 3 months, 1 year, 2 years ]

Secondary Outcome Measures:
  • major outcomes in subgroups of patients with severe and mild OSAS [ Time Frame: 3 months, 1 year, 2 years ]
  • circulating markers of inflammation and cardiovascular risk [ Time Frame: 3 months, 1 year, 2 years ]
  • side effects [ Time Frame: 3 months, 1 year, 2 years ]
  • nocturnal respiratory disturbances [ Time Frame: 3 months, 1 year, 2 years ]
  • treatment adherence [ Time Frame: 3 months, 1 year, 2 years ]

Enrollment: 208
Study Start Date: January 2006
Study Completion Date: March 2014
Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
constant CPAP
Device: constant CPAP devices
different CPAP mode
Experimental: 2
automatic CPAP
Device: automatic CPAP devices
different CPAP mode

Detailed Description:
  1. To investigate whether computer controlled continuous positive airway pressure (autoCPAP) improves subjective sleepiness, quality of life, objective vigilance, and nocturnal respiration to a similar degree as conventional fixed continuous positive airway pressure in the initial phase of treatment and over the subsequent 2 years during home therapy
  2. To investigate the cost of autoCPAP compared to fixed CPAP therapy
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Excessive sleepiness, and Epworth Sleepiness Score > or = 8
  • Apnea- Hypopnea-Index (AHI) > or = 10/hour
  • Age 18-75

Exclusion Criteria:

  • Psychophysiological incapacity to perform questionnaires
  • Other sleep disorders
  • Psychiatric disease requiring treatment
  • Previous CPAP therapy
  • Previous uvulopalatopharyngoplasty
  • Chronic nasal obstruction that required treatment for more than 1 month
  • Cancer
  • COPD, with FEV1 < 50% predicted
  • Symptomatic cardiovascular disease requiring treatment defined as congestive heart failure > NYHA II
  • Previous stroke with neurological residuum
  • Cheyne-Stokes respiration
  • Chronic pain syndromes, fibromyalgia
  • Drug or alcohol addiction
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00280800


Locations
Switzerland
Pulmonary Division and Sleep Disorders Center, University Hospital of Zurich
Zürich, Switzerland, CH-8091
Sponsors and Collaborators
Konrad E. Bloch
University of Zurich
Kantonsspital Münsterlingen
Zuercher Hoehenklinik Wald
Cantonal Hospital of St. Gallen
Investigators
Study Chair: Konrad E Bloch, MD Pulmonary Division and Sleep Disorders Center, University Hospital of Zürich, Switzerland
  More Information

Responsible Party: Konrad E. Bloch, Professor, University of Zurich
ClinicalTrials.gov Identifier: NCT00280800     History of Changes
Other Study ID Numbers: EK 1187
First Submitted: January 20, 2006
First Posted: January 23, 2006
Last Update Posted: May 15, 2014
Last Verified: May 2014

Keywords provided by Konrad E. Bloch, University of Zurich:
randomized
controlled
double blind
effectiveness
auto CPAP
treatment
sleep apnea

Additional relevant MeSH terms:
Sleep Disorders, Intrinsic
Apnea
Sleep Apnea Syndromes
Sleep Apnea, Obstructive
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Signs and Symptoms
Dyssomnias
Sleep Wake Disorders
Nervous System Diseases